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Abstract: Schizophrenia-like illnesses occur in a variety of medical and neurological conditions 
but to date have not been described in association with aceruloplasminemia. Aceruloplasmin-
emia is an autosomal recessive disorder of iron metabolism which leads to iron deposition in 
the basal ganglia, thalamus, cerebellum and hippocampus and which usually presents in middle 
age with extrapyramidal symptoms and dementia. We describe a 21-year-old woman on treat-
ment for aceruloplasminemia who presented with schizophrenia-like psychosis and declining 
function in the absence of neurological signs. Neuropsychological testing showed signiﬁ  cant 
dominant hemisphere deﬁ  cits. Magnetic resonance imaging showed bilateral iron deposition 
in the cerebellar dentate nuclei and thalami, frontal atrophy, and periventricular white matter 
hyperintensities. Functional imaging suggested global hypoperfusion. The clinical, cognitive 
and imaging ﬁ  ndings were not typical for either aceruloplasminemia or schizophrenia alone 
and the possible relationship between the two disorders is discussed with particular reference 
to implications for our understanding of schizophrenia.
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Introduction
Numerous medical conditions are known to produce psychotic symptoms that resemble 
schizophrenia, including metabolic and neurological disorders (Cummings 1996). We 
describe a young woman with schizophrenia-like psychotic symptoms and functional 
decline in the context of diagnosed aceruloplasminemia, a disorder which has not been 
previously associated with psychosis.
Case history
BB was a 21-year-old woman referred for neuropsychiatric assessment on the back-
ground of a psychotic illness and a conﬁ  rmed diagnosis of aceruloplasminemia. BB’s 
family had noticed an initial 18-month period of functional and social deterioration, 
poor school performance, social withdrawal, and periods of verbal aggression. She 
was initially treated by her general practitioner with ﬂ  uvoxamine, but later deteriorated 
with frank persecutory delusions, auditory hallucinations, aggression and poor self-
care over the subsequent 6 months. The local mental health team began risperidone 
3 mg/day, which treated the positive symptoms but did not arrest her functional decline. 
BB completely avoided all social contact, only watched television and was unable to 
manage her activities of daily living. She was referred for neuropsychiatric assess-
ment to further elucidate the contribution of the aceruloplasminemia to her cognitive 
and functional abilities.
BB had no formal psychiatric history. She had mild learning difﬁ  culties as a child, 
but attended mainstream schooling. At age 15 she had seen a school psychologist 
after telling other students she was going to be reborn as a prince. BB had been diag-
nosed with aceruloplasminemia at age 20, after detection of abnormal liver function 
and hyperferritinemia of 1700 μg/L (15–200). Liver biopsy conﬁ  rmed signiﬁ  cant Neuropsychiatric Disease and Treatment 2006:2(4) 578
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iron overload without ﬁ  brosis, and desferrioxamine 20 g 
thrice weekly was initiated. The diagnosis of aceruloplas-
minemia was highly suspected because a paternal uncle 
had been diagnosed with the disorder. The patient and her 
maternal uncle share a common, unique mutation for this 
disorder. BB’s uncle had been described by the family as 
suffering long-standing behavioral problems but had never 
been given a psychiatric diagnosis. There was a history of 
consanguinity, with her parents’ grandparents being ﬁ  rst 
cousins.
BB’s delivery was normal but for a prolonged rupture 
of membranes. She walked at 12 and talked at 15 months. 
She was a shy and clingy child at school who had verbal and 
social difﬁ  culties. She left school in Year 11 and attended 
a technical college where she also struggled. She had not 
worked or attended school since the age of 18. There was 
no history of substance abuse.
On mental state examination, she was cooperative but 
only established superﬁ  cial rapport. Speech was of normal 
rate and volume with limited spontaneity. Mood was euthy-
mic and affect reactive, although blunted. At the time of 
assessment there were no psychotic or depressive symptoms 
and no insight into her previous symptoms or functional 
impairment.
On bedside cognitive testing, she scored 25/30 on the 
Mini-Mental State Examination (Folstein et al 1975), and 
75/100 on the Neuropsychiatry Unit Cognitive screening tool 
(NUCOG) (Walterfang et al 2006), each signiﬁ  cantly below 
expected age norms. Hence, the patient was referred for a 
neuropsychological review, and information from an earlier 
assessment was obtained as a baseline. Physical examina-
tion was unremarkable. She had some mild conjunctival 
pallor but no Kaiser-Fleischer rings. She had no abdominal 
organomegaly. There were no abnormal movements, primi-
tive reﬂ  exes or other neurological signs.
BB had normal electrolytes, hepatic, renal and thyroid 
function. Hemoglobin was low at 101 g/L” (115–150) with 
normal platelet and white cell counts and B12 and folate lev-
els. Serum ferritin was still elevated at 688 μg/L (15–200).
Magnetic resonance imaging (MRI) showed global 
atrophy, most marked over the frontal lobes. She had a 
greater-than-expected load of periventricular white matter 
hyperintensities, and a thin anterior callosum. Iron deposi-
tion was evident in the dentate nucleus of the cerebellum and 
the thalamus, and to a lesser degree throughout the whole 
cerebral cortex, but not in the basal ganglia (Figure 1). 
Single-photon emission computed tomography (SPECT) 
showed global hypoperfusion. MRI of the abdomen showed 
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borderline general intellectual ability suggesting a signiﬁ  cant 
decline. She performed signiﬁ  cantly better on non-verbal 
than verbal tasks, which were poor, in addition to poor verbal 
memory. Working memory was very poor, and psychomo-
tor speed and speed of information processing was slowed. 
She had strengths in visuospatial/constuctional abilities 
and memory. She displayed good performances on frontal-
based tasks tapping into generating new strategies, response 
monitoring, inhibition, planning and organization, and mental 
set-shifting, although she was at times signiﬁ  cantly slower 
than her age-peers. These deﬁ  cits were also borne out in an 
occupational therapy assessment, where her deﬁ  cits of new 
learning were manifest in requiring frequent repetition to 
learn new tasks, and slow mental information processing 
impaired her ability to deal with everyday ﬁ  nancial and 
logistical tasks.
The patient’s risperidone was increased to 5 mg per 
day, with some improvement in her degree of negative 
symptoms without re-emergence of positive symptoms. 
Eighteen months after assessment, she had begun a beauty 
therapy course.
Discussion
Ceruloplasmin (CP) is a 132-kDa glycoprotein that is 
predominantly synthesized in the liver but does not cross 
the blood brain barrier and is produced by astrocytes in the 
CNS (Klomp and Gitlin 1996). Copper atoms incorporated 
during the synthesis of CP allow it to shuttle electrons and 
act as a multicopper ferro-oxidase. In iron homeostasis CP 
oxidises Fe2+ (ferrous iron) to Fe3+ (ferric iron) so that the 
latter can bind to transferrin and be trafﬁ  cked throughout 
the body. Fe2+ is required as a cofactor for many biological 
processes but is capable of generating toxic hydroxyl and 
superoxide free radicals, and hence must be tightly bound 
to proteins during transport and storage (De Silva et al 
1996). CP promotes the loading of iron onto transferrin, 
allowing Fe3+ efﬂ  ux out of cells and preventing oxidative 
damage caused by Fe2+ (Qian and Ke 2001; Hellman and 
Gitlin 2002).
In aceruloplasminemia, an autosomal recessive disor-
der occurring in 1 in 2 million non-consanguinous births 
(Miyajima et al 1999), mutations in the CP gene result in 
absent ferroxidase activity of CP leading to the deposition 
of iron in the CNS, retina, pancreatic cells, liver, spleen, and 
ovaries (Yoshida et al 1995; Hellman and Gitlin 2002). The 
astrocyte-speciﬁ  c form of CP plays a key role in regulating 
iron levels in the CNS and in preventing free radical injury 
(Patel et al 2002). The major sites of CNS iron deposition in 
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Figure 1 MRI images (with annotating arrows) demonstrating low signal on 
T2-weighted axial imaging representing iron deposition in the basal ganglia (1a) and 
dentate nucleus of the cerebellum (1b). Sagittal T1-weighted image demonstrates 
anterior callosal thinning (1c), likely secondary to frontal cortical atrophy as seen 
on a T2-weighted axial slice (1d). Fluid-attenuation inversion recovery (FLAIR) axial 
slice shows periventricular “cupping” (1e).
no evidence of ovarian iron deposition. EEG was normal. 
A screen for lysosomal and other storage disorders on 
peripheral blood lymphocytes and cultured ﬁ  broblasts was 
normal.
Neuropsychological assessment showed a woman of low-
average to average premorbid intellect, but demonstrating Neuropsychiatric Disease and Treatment 2006:2(4) 580
Walterfang et al
aceruloplasminemia are the basal ganglia, cerebellar dentate 
nuclei, red nucleus, thalamus, and hippocampus (Miyajima 
2003). The pattern of deposition, which is greatest in the 
globus pallidus and putamen (Miyajima 2003), occurs in 
regions where vulnerable perivascular astrocyte populations 
are distributed (Klomp and Gitlin 1996). The sites of great-
est iron concentration in healthy individuals are the basal 
ganglia, red nucleus, and deep nuclei of the cerebellum 
(Yoshida et al. 1995).
Aceruloplasminemia presents with retinal degenera-
tion, diabetes mellitus and neurological symptoms, usu-
ally extrapyramidal signs, dyskinesia, dystonia, and a 
subcortical dementia in the ﬁ  fth or sixth decade (Nittis 
and Gitlin 2002). Neurological signs may be preceded for 
many years by diabetes mellitus and anemia due to inef-
ﬁ  cient iron delivery. MRI ﬁ  ndings typically show marked 
T2 hypointensity in these regions of maximal iron deposi-
tion (Morita et al. 1995; Daimon et al. 1999; Grisoli et al. 
2005), although may also show subtle posterior white 
matter tract hyperintensity and subtle superﬁ  cial cerebral 
and cerebellar cortical hypointensity (Grisoli et al. 2005). 
White matter tract changes may reﬂ  ect a disconnection of 
projecting ﬁ  bres from key relay nuclei such as the thalamic 
nuclei, with subsequent subtle cortical changes (Grisoli 
et al. 2005).
While the clinical presentation was predominantly one 
of schizophrenia with no classical neurological features of 
aceruloplasminemia, the imaging ﬁ  ndings of thalamic and 
cerebellar involvement suggest that even at this early stage 
CNS manifestations of aceruloplasminemia are present but 
neurologically silent. BB’s imaging also revealed prominent 
frontal cortical atrophy, white matter hyperintensities and 
thinning of the corpus callosum which are not characteristic 
of CP (Miyajima 2003) and no other pathological cause 
was found for these changes. Regional cortical and callosal 
atrophy of this nature, as opposed to subtle cortical and white 
matter intensity changes, have not previously been reported 
in aceruloplasminemia.
The MRI ﬁ  ndings of signiﬁ  cant iron deposition in 
the thalamus and the dentate nucleus of cerebellum may 
be relevant to her schizophrenia-like presentation. The 
repeated demonstration of subtle abnormalities in structure 
and function of the cerebellum in schizophrenia popula-
tions has also led to its implication in the development of 
schizophrenia, possibly due to disruptions to the cerebello-
thalamo-cortico-cerebellar loop (Andreasen et al. 1998). 
Pathology in the thalamus may also disrupt this circuit, 
and given that the thalamus has similarly been implicated 
in the pathogenesis of schizophrenia (Clinton and Meador-
Woodruff 2004), it is feasible that iron deposition-related 
pathology in these regions may be, in a vulnerable brain, 
psychotogenic.
The development of psychosis in BB, atypical for 
aceruloplasminemia, could be seen to represent an “organic” 
example of the “two hit” model of schizophrenia. The effects 
of aceruloplasminemia through pathology in dentate and 
thalamic regions in BB may have interacted with an early 
frontal insult, such as perinatal hypoxia or other obstetric 
complications – known risk factors for the later develop-
ment of schizophrenia (Cannon et al. 2002a, 2002b) – or 
with other unknown biological vulnerabilities, to result 
in schizophrenia-like symptoms during the typical age of 
onset for the disorder. There is a strong relationship between 
anatomic abnormalities in the hippocampus, cerebellum and 
thalamus and schizophrenia (Harrison 1999; Shenton et al. 
2001) and iron deposition in these regions during adolescence 
may have triggered a vulnerability to schizophrenia-like 
psychosis in this patient.
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